# Successful use of stapokibart as a biological therapy for allergic fungal rhinosinusitis: a case report

## TL;DR

A patient with allergic fungal rhinosinusitis showed significant improvement after treatment with stapokibart, a new biological therapy.

## Contribution

This is the first reported case demonstrating stapokibart's effectiveness in treating refractory allergic fungal rhinosinusitis.

## Key findings

- The patient showed significant clinical improvement after four weeks of stapokibart treatment.
- Lab tests showed a substantial drop in eosinophils and IgE levels by week 16.
- A follow-up CT scan confirmed complete resolution of sinus inflammation.

## Abstract

To present a rare, to our knowledge previously undescribed, case of successful AFRS management using stapokibart (CM310).

The laboratory, immunological, symptom scores and imaging datas before and after stapokibart treatment were evaluated to determine the effect of stapokibart on AFRS.

After four weeks of treatment, the patient showed significant clinical improvement, including a marked reduction in nasal polyp size and the near-complete return of normal olfaction. By week 16, lab tests confirmed a substantial drop in eosinophils and IgE, and a follow-up CT scan showed complete resolution of sinus inflammation. The patient reported high satisfaction due to a major improvement in quality of life.

This pioneering case demonstrates that stapokibart, a novel anti-IL-4Rα antibody, is a promising and effective treatment for refractory AFRS, showing a rapid onset of action and sustained control of type 2 inflammation.